PDCD1 and non-small cell lung carcinoma: Tumors with high TMB levels have demonstrated improved clinical efficacy of PD-1/PD-L1 Ab treatment in a range of cancer types, including NSCLC [245,433], UC [420], and others [242,324,434,435].